TELES AG Informationstechnologien: Acquisition of the pharmaceutical supplier EURO RX GmbH

Berlin (pta034/30.11.2021/15:15 UTC+1) TELES AG Informationstechnologien (ISIN DE000A289B07 / WKN A289B0) acquires the majority of the Europe-wide pharmaceutical supplier EURO RX Arzneimittel GmbH (EURO RX). The acquisition of the drug supplier for specialty drugs is another logical step to significantly strengthen the pharmaceuticals expansion field.

Like TELES, EURO RX is a pioneer in the digitization of value chains. In order to guarantee optimal pharmaceutical care for patients and to offer pharmacies in Europe integrated solutions for stable and reliable delivery, EURO RX invested in the automation of procurement at an early stage.

Together with certified pharmacies, EURO RX mainly supplies specialty drugs with which, among other things, cancer diseases or autoimmune deficits in patients are treated.

With this acquisition, TELES is also pursuing the goal of transferring its expertise in the secure management of large amounts of data and its analysis to the pharmaceutical market. TELES had already acquired the majority in the GVL pharmacy data center in autumn 2021.

The development of software for telecommunications companies is and will remain a pillar of the company and TELES will be actively looking for further acquisitions in this market as well.

Oliver Olbrich
CEO

(end)

Emitter:	TELES AG Informationstechnologien Ordensmeisterstraße 15-16 12099 Berlin Germany
Contact Person:	Oliver Olbrich
Phone:	+49 30 399 28 00
E-Mail:	legal@teles.com
Website:	www.teles.com
ISIN(s):	DE000A289B07 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart